PerkinElmer, Inc., a leading global company in the life sciences and diagnostics sectors, is headquartered in the United States. Founded in 1937, PerkinElmer has established itself as a pioneer in providing innovative solutions across various industries, including healthcare, environmental testing, and food safety. With a strong presence in North America, Europe, and Asia, the company offers a diverse range of core products and services, such as analytical instruments, reagents, and software solutions. PerkinElmer's commitment to advancing human and environmental health is reflected in its cutting-edge technologies and comprehensive support services. Recognised for its significant contributions to the field, PerkinElmer has achieved notable milestones, including advancements in genetic testing and diagnostics. This positions the company as a trusted partner in the scientific community, dedicated to improving lives through innovation.
How does Perkinelmer's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Perkinelmer's score of 31 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2021, PerkinElmer reported total carbon emissions of approximately 29,928,000 kg CO2e, comprising 7,579,000 kg CO2e from Scope 1 and 22,349,000 kg CO2e from Scope 2 emissions. This marked a reduction from 2020, when total emissions were about 27,774,000 kg CO2e, with Scope 1 emissions at 9,219,000 kg CO2e, Scope 2 at 27,748,000 kg CO2e, and Scope 3 emissions (business travel) at 1,569,000 kg CO2e. PerkinElmer has set ambitious climate commitments, aiming for net carbon neutrality by 2040. The company has raised its reduction target to a 50.4% decrease in Scope 1 and 2 emissions by 2032, compared to 2020 levels. This is an increase from their previous goal of a 30% reduction by 2030, aligning with the latest guidance from the Science Based Targets Initiative (SBTi). Overall, PerkinElmer is committed to significant emissions reductions and has demonstrated progress in its climate initiatives, reflecting a strong commitment to sustainability within the pharmaceuticals, biotechnology, and life sciences sector.
Access structured emissions data, company-specific emission factors, and source documents
2020 | 2021 | |
---|---|---|
Scope 1 | 9,219,000 | 0,000,000 |
Scope 2 | 27,748,000 | 00,000,000 |
Scope 3 | 1,569,000 | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Perkinelmer is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.